- cafead   Apr 29, 2019 at 12:22: PM
via Two months after Bayer and its Finnish partner Orion reported positive late-stage data for its prostate cancer drug darolutamide, the German drugmaker has convinced the FDA to grant priority review on its NDA.
article source
article source